Table 1.

Renal function and kidney volume in patients with late-stage ADPKD at baseline and after 6-mo follow-upa

PatientAgeGFR (ml/min)VTot (ml)VCys (ml)VInt (ml)VPar (ml)
Baseline6 MoΔ%Baseline6 MoΔ%Baseline6 MoΔ%Baseline6 MoΔ%Baseline6 MoΔ%
14148.745.9−5.7226924578.3134714386.864472712.82782925.3
24934.930.9−11.5218122010.9156115831.4464461−0.61561570.7
34832.125.3−21.21716196014.28949819.760073121.822224912.0
45836.832.0−13.0146915706.995810327.737441711.5137120−11.8
55386.777.7−10.4340236076.0277429426.134838410.22802810.4
63845.042.6−5.31722199215.61211140015.635642619.61551656.4
748100.8101.81.0359638727.7309934009.7229211−7.8267260−2.6
84186.890.84.6183218903.28208685.8642640−0.33703833.5
93569.973.95.71756193110.096610569.25025427.928733416.4
103971.976.76.714571354−7.1797736−7.6437403−7.8223215−3.6
113867.179.318.2338435936.22094235012.2976949−2.8314294−6.2
125428.523.4−17.9429545485.928052792−0.51207142518.028233117.2
133387.894.17.2228223854.5137114405.06116313.32993145.0
Mean44.261.361.1−3.2241225666.3159216946.25696116.62522613.3
SD7.924.928.411.59359995.78258805.926931110.169788.5
P 0.8574 (NS)<0.01<0.050.0502 (NS)0.1267 (NS)
  • a ADPKD, autosomal dominant polycystic kidney disease; VCys, cyst volume; VInt, intermediate volume; VPar, parenchymal volume; VTot, total volume.